Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4700421

NCCCCN1CCCC1.O=C(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.50
CHRM4 P08173 2/20 0.50
CHRM5 P08912 2/20 0.50
CHRM1 P11229 2/20 0.50
CHRM3 P20309 2/20 0.50
CYP1A2 P05177 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CPB2 Q96IY4 3/20 0.46
HRH3 Q9Y5N1 1/20 0.43
ARG1 P05089 4/20 0.41
ARG2 P78540 3/20 0.41
SIGMAR1 Q99720 1/20 0.40
HRH2 P25021 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3522567 0.91 CPB2 (0.47) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL4700418 0.82 L3MBTL1 (0.58) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL5616394 0.82 CYP1A2 (0.47) CYP1A2MAPK1SMN1; SMN2CPB2HRH3
Trifluoroacetic Acid SCHEMBL16700590 0.81 KDM4E (0.48) CYP1A2MAPK1SMN1; SMN2CPB2HRH3
SCHEMBL378444 0.80 HRH3 (0.65) CYP1A2MAPK1SMN1; SMN2HRH3SIGMAR1
Trifluoroacetic Acid SCHEMBL16701135 0.80 CYP1A2 (0.48) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL3749229 0.79 SMN1; SMN2 (0.67) SMN1; SMN2ARG1ARG2
Trifluoroacetic Acid SCHEMBL28941864 0.79 HRH3 (0.50) CYP1A2MAPK1SMN1; SMN2CPB2HRH3
Trifluoroacetic Acid SCHEMBL21994721 0.78 CYP1A2 (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL21994719 0.78 CYP1A2 (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926737-B1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-03-15 EP claimed
EP-1926737-B1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-03-15 EP disclosed
EP-1926737-A1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 EP disclosed
WO-2007031428-A1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 WO disclosed
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BARTKOVITZ DAVID J 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BRAF, RAF1, MAP3K7 CHRM2 4372/4885CHRM4 4689/4885CHRM5 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.